Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Trial details
- Registry ID
- NCT06500273
- Drugs studied
- Cyclophosphamide, Fludarabine, Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™, cemacabtagene ansegedleucel
TrialRedline tracks 2 clinical trials sponsored by Allogene Therapeutics: 2 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCLNCT06500273 | Cyclophosphamide, Fludarabine, Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™, cemacabtagene ansegedleucel | Recruiting | 2027-12Estimated |
| Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell TherapyNCT05714345 | ALLO-501A, ALLO-647, Cyclophosphamide, Fludarabine | Terminated | 2024-02-20Actual |
Names as written in the registry records.
NCT06500273 · Allogene Therapeutics
Before: 24 Aug 2027. After: Dec 2027.